Clinical Trial Update: Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Mirdametinib alone or with radiotherapy for germline and sporadic NF1-altered high-grade glioma; status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• High-grade Glioma
• Neurofibromatosis Type

Drugs mentioned

• Mirdametinib (mirdametinib)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Neurofibromatosis 1 (NF1) | Phase 2 | Status: NOT_YET_RECRUITING